×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
FDA sends CRL to Clovis in last-gasp bid for Rubraca nod
Fierce Pharma
Six months after filing for bankruptcy, Clovis Oncology was hoping for a last gasp win for fading cancer drug Rubraca.
10 months ago
Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4
The Globe and Mail
Detailed price information for Clovis Oncology Inc (CLVS-Q) from The Globe and Mail including charting and trades.
1 week ago
Rubraca sheds positive light for PARP inhibitors in endometrial cancer
Clinical Trials Arena
On 18 March 2024, positive Phase II results of Clovis Oncology's Rubraca were presented at the Society of Gynecologic Oncology conference,...
1 month ago
EC approves pharmaand’s Rubraca as advanced ovarian cancer maintenance treatment
PMLiVE
The European Commission (EC) has approved pharmaand's (pharma&) Rubraca (rucaparib) as a first-line maintenance treatment for advanced...
5 months ago
Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period (2019-2032), Assesses ...
PR Newswire
PRNewswire/ -- DelveInsight's Small-Cell Lung Cancer Market Insights report includes a comprehensive understanding of current treatment...
6 months ago
Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference
The Globe and Mail
Detailed price information for Clovis Oncology Inc (CLVS-Q) from The Globe and Mail including charting and trades.
1 week ago
Amid FAP-Targeted Theranostic Boom, Indian Cancer Center Shares Promising Early Experience
Precision Medicine Online
Investigators at Bengaluru's HCG Hospital are assessing fibroblast activation protein-targeted radioligands, which have recently attracted...
10 months ago
Cancer Focused Clovis Oncology Files For Bankruptcy
Yahoo Finance
Clovis Oncology Inc (NASDAQ: CLVS) has voluntarily initiated a Chapter 11 proceeding in the U.S. Bankruptcy Court and will seek to sell its...
16 months ago
Embattled Clovis Oncology Files for Chapt. 11, Sells Radioligand Therapeutic to Novartis
BioSpace
Embattled Clovis Oncology Files for Chapt. 11, Sells Radioligand Therapeutic to Novartis ... Clovis Oncology filed for Chapter 11 bankruptcy and...
16 months ago
Novartis pays $40M cash for biotech's radiopharmaceutical tech
Fierce Biotech
Novartis is offering up to $425M in biobucks for exclusive licensing rights to 3B Pharmaceuticals' FAP-targeting peptide tech.
12 months ago